目的 探討三拗片聯(lián)合特布他林治療咳嗽變異性哮喘的臨床研究。方法 選取2019年8月-2020年4月在青島西海岸新區(qū)中醫(yī)醫(yī)院門診急診治療的咳嗽變異性哮喘患者90例，隨機分為對照組（n=45）和治療組（n=45）。對照組經(jīng)霧化器吸入硫酸特布他林霧化液，2.5 mg/次，3次/d；治療組在對照組治療的基礎(chǔ)上口服三拗片，2片/次，3次/d。兩組均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組咳嗽癥狀的緩解和消失時間。比較兩組嗜酸性粒細(xì)胞和肺功能的變化情況。結(jié)果 治療后，治療組的總有效率95.56%，顯著高于對照組的73.33%（P<0.05）。治療后，治療組咳嗽緩解時間和咳嗽消失時間明顯短于對照組（P<0.05）。治療后，兩組患者血清中嗜酸性粒細(xì)胞水平明顯低于治療前水平（P<0.05）；治療組治療后血清中嗜酸性粒細(xì)胞水平顯著低于對照組（P<0.05）。治療后，兩組患者肺活量（FVC）、第1秒用力呼氣量（FEV1）和最大呼氣流量（PEF）明顯高于治療前（P<0.05）；治療組治療后FVC、FEV1和PEF顯著高于對照組（P<0.05）。結(jié)論 三拗片聯(lián)合特布他林治療咳嗽變異性哮喘具有較好的臨床療效，能降低嗜酸性粒細(xì)胞水平，有效改善臨床癥狀和肺功能指標(biāo)，具有一定的臨床推廣應(yīng)用價值。

Objective To study the clinical effect of San'ao Tablets combined with terbutaline in the treatment of cough variant asthma. Methods A total of 90 patients with cough variant asthma admitted to West Coast New District Hospital of Traditional Chinese Medicine outpatient and emergency from August 2019 to April 2020 were randomly divided into control group (n=45) and treatment group (n=45). The control group inhaled Terbutaline Sulphate Solution for Nebulization, 2.5 mg/time, three times daily. The treatment group was po administered with San'ao Tablets on the basis of the control group, 2 tablets/time, three times daily. All patients were treated for 14 days. The clinical efficacy of the two groups was observed, and the relief and disappearance time of cough symptoms in the two groups was compared. The changes of eosinophils and lung functions were compared between the two groups. Results The total effective rate in the treatment group was 95.56%, which was significantly higher than 73.33% in the control group (P < 0.05). After treatment, the remission time and disappearance time of cough in the treatment group were significantly shorter than those in the control group (P < 0.05). After treatment, the serum level of eosinophils in both groups was significantly lower than that before treatment (P < 0.05). The serum level of eosinophils in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, vital capacity (FVC), forced expiratory capacity (FEV1) and maximum expiratory flow (PEF) in the two groups were significantly higher than those before treatment (P < 0.05). After treatment, FVC, FEV1 and PEF in the treatment group were significantly higher than those in the control group (P < 0.05). Conclusion San'ao Tablets combined with terbutaline has good clinical effect in the treatment of cough variant asthma, and can reduce eosinophil levels, also can effectively improve clinical symptoms and lung function indicators, which has a certain clinical application value.

R974

天津市衛(wèi)生和計劃生育委員會中醫(yī)西醫(yī)結(jié)合科研課題（2015098）